SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Maslowski John Michael

(Last)

(First)

(Middle)

405 EAGLEVIEW BOULEVARD

(Street)

EXTON

19341

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/14/2014

3. Issuer Name and Ticker or Trading Symbol
Fibrocell Science, Inc. [ FCSC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	V.P., Scientific Affairs

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	480	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to Purchase Common Stock	⁽¹⁾	10/06/2019	Common Stock	4,000	$18.75	D
Option to Purchase Common Stock	⁽²⁾	01/14/2021	Common Stock	13,600	$15.5	D
Option to Purchase Common Stock	⁽³⁾	07/19/2023	Common Stock	17,500	$5.49	D
Option to Purchase Common Stock	⁽⁴⁾	01/17/2024	Common Stock	20,000	$4.95	D
Option to Purchase Common Stock	⁽⁵⁾	05/13/2024	Common Stock	20,000	$2.94	D
Warrant to Purchase Common Stock	01/21/2011	12/31/2016	Common Stock	960	$6.25	D

Explanation of Responses:

1. 50% of the Option to Purchase Common Stock vested on October 6, 2010 and 50% of the Option to Purchase Common Stock vested on the date the Issuer received approval for azficel-T.

2. 50% of the Option to Purchase Common Stock vested on January 14, 2011, 25% of the Option to Purchase Common Stock vested on January 14, 2012 and 25% of the Option to Purchase Common Stock vested on January 14, 2013.

3. 25% of the Option to Purchase Common Stock vested on July 19, 2013, 25% of the Option to Purchase Common Stock will vest on July 19, 2014, 25% of the Option to Purchase Common Stock will vest on July 19, 2015 and 25% of the Option to Purchase Common Stock will vest on July 19, 2016; in each case provided the reporting person is providing services to the Issuer on each vesting date.

4. 25% of the Option to Purchase Common Stock will vest on January 17, 2015, 25% of the Option to Purchase Common Stock will vest on January 17, 2016, 25% of the Option to Purchase Common Stock will vest on January 17, 2017, and 25% of the Option to Purchase Common Stock will vest on January 17, 2018; in each case provided the reporting person is providing services to the Issuer on each vesting date.

5. 25% of the Option to Purchase Common Stock will vest on May 13, 2015, 25% of the Option to Purchase Common Stock will vest on May 13, 2016, 25% of the Option to Purchase Common Stock will vest on May 13, 2017, and 25% of the Option to Purchase Common Stock will vest on May 13, 2018; in each case provided the reporting person is providing services to the Issuer on each vesting date.

	/s/ John Maslowski	05/23/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.